Am J Transplant, Volume 20, Suppl 3 Archives - Page 20 of 223 - ATC Abstracts

2020 American Transplant Congress
RN Specialty Practice to Optimize Enteric Hyperoxaluria Management – A Qi Project
B. M. Amberg, M. R. D'Costa, J. L. Wells-Pittman, A. R. Frodermann, E. M. Dahlen, G. M. Davidson, T. L. Mueller, C. A. Nash, T. I. Schnell, H. Amer, J. C. Lieske
Mayo Clinic, Rochester, MN
*Purpose: Optimal management of enteric hyperoxaluria (EH) requires institution of a strict low-fat, low oxalate diet and use of oral calcium supplements as oxalate binders.…
2020 American Transplant Congress
Organ Donation in Perú: Why are We Failing? Conclusions from the Last 5 Years
M. Moreno Gonzales, J. Duran, O. Ponce, G. Navarro, M. Benavides
Instituto Nacional de Salud del Niño de San Borja, Lima, Peru
*Purpose: The scarcity of deceased donor organs is still an unmet need in transplantation worldwide. This dilemma is significantly important in several Latin American nations.…
2020 American Transplant Congress
The Heart of the Matter: The Impact of the 2018 Heart Allocation Policy at a Single Organ Procurement Organization
A. J. Boyer, J. B. Nave, C. A. Hostetler, C. C. Muse, R. A. Squires, J. P. Orlowski
LifeShare Transplant Donor Services of Oklahoma, Oklahoma City, OK
*Purpose: In 2018, allocation policy changed with the goal of lowering waitlist mortality by increasing access to donor hearts. We sought to describe the impact…
2020 American Transplant Congress
Effect of Intravenous Ferric Gluconate on Post Heart Transplant Outcomes in Patients Bridged with Left Ventricular Assist Devices
N. Krepostman, D. Kim, D. Masic, S. Kuhrau, J. Negrelli, M. Liebo, E. Raichlin, A. Heroux, H. Basha
Internal Medicine, Loyola University Medical Center, Maywood, IL
*Purpose: Our study examined the effect of intravenous (IV) ferric gluconate compared to oral iron repletion in reducing 30-day hospital readmissions and all-cause mortality in…
2020 American Transplant Congress
Case Series of Belatacept for Calcineurin Inhibitor Sparing after Lung Transplantation
H. Patel, C. R. Ensor, R. D. Davis, L. Bogar, D. Colella, M. Kildea, J. Kim, A. Satterthwaite, D. Ventura, C. Gries
AdventHealth, Orlando, FL
*Purpose: Belatacept is a recombinant soluble fusion protein which selectively blocks T-cell co-stimulation. It received initial FDA approval for prophylaxis of organ rejection in Epstein-Barr…
2020 American Transplant Congress
Incidence and Influencing Factors of Venous Thromboembolism after Lung Transplantation
L. Fan¹, J. Chen², B. Wu¹, Z. Zhai³
¹Pulmonary and Critical Care Medicine, Wuxi People’s Hospital, Wuxi, China, ²Thoracic Surgery, Wuxi People’s Hospital, Wuxi, China, ³Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China
*Purpose: To analyze the incidence and influencing factors of venous thromboembolism (VTE) after lung transplantation.*Methods: This study retrospectively analyzed the clinical data of 375 lung…
2020 American Transplant Congress
Beta Cell Replacement Therapy in Nonuremic Patients with Brittle T1DM Allows for Durable Long Term Insulin Independence Halting Progression of Secondary Diabetic Complications
P. J. Bachul¹, D. J. Grybowski¹, R. Anteby², L. Basto¹, L. Perea¹, K. Golab¹, L. Wang¹, M. Tibudan¹, A. Perez-Gutierrez¹, M. Komorniczak³, A. Lucander¹, P. Borek¹, M. Dimitrov¹, J. Fung¹, P. Witkowski¹
¹Surgery, University of Chicago, Chicago, IL, ²Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ³Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
*Purpose: Beta cell replacement therapy in form of pancreas or islet transplantation is the only effective treatment for patients suffering from hypoglycemic unawareness despite intensive…
2020 American Transplant Congress
Impact of Kidney Transplant Type and Previous Transplant on Baseline Donor-Derived Cell Free DNA
K. K. Sureshkumar, B. Chopra
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA
*Purpose: Donor derived-cell free DNA (dd-cfDNA) is a biomarker useful in predicting acute rejection in renal allografts. The technology uses next generation sequencing and does…
2020 American Transplant Congress
Protection Role of microRNA let-7 in Hepatic Ischemia Reperfusion Injury by Inhibiting JAK-STAT3 Pathway
C. Sun¹, Y. Hou², S. Huang³, L. Wu¹
¹Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, ²Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ³Department of General Surgery, Guangdong General Hospital, Guangzhou, China
*Purpose: Ischemia reperfusion injury (IRI) is an inevitable event in conventional organ transplant procedure and affects the prognosis in post-transplantation. Increasing evidence suggests that microRNA…
2020 American Transplant Congress
Synergistic Anticancer Effect of Metformin in Combination with Immunosuppressant on Hepatocellular Carcinoma Cell Lines
S. Suh¹, Y. Choi¹, K. Lee²
¹Surgery, Chung-Ang University, College of Medicine, Seoul, Korea, Republic of, ²Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of
*Purpose: After liver transplantation (LT), immunosuppression is needed to avoid rejection and graft loss, however, it can stimulate hepatocellular carcinoma (HCC) recurrence and progression. Previous…